StockNews.com downgraded shares of Karyopharm Therapeutics (NASDAQ:KPTI – Free Report) from a buy rating to a hold rating in a report issued on Friday.
A number of other analysts have also recently issued reports on KPTI. Robert W. Baird reduced their target price on shares of Karyopharm Therapeutics from $8.00 to $5.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. Piper Sandler upped their price objective on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a report on Friday, November 1st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $3.00 price objective on shares of Karyopharm Therapeutics in a report on Wednesday, August 7th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.
View Our Latest Stock Analysis on Karyopharm Therapeutics
Karyopharm Therapeutics Trading Up 8.7 %
Karyopharm Therapeutics (NASDAQ:KPTI – Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.01. The firm had revenue of $38.78 million for the quarter, compared to analysts’ expectations of $37.86 million. During the same period last year, the business earned ($0.30) earnings per share. Analysts expect that Karyopharm Therapeutics will post -0.94 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Karyopharm Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in KPTI. Ikarian Capital LLC boosted its stake in Karyopharm Therapeutics by 2.3% during the 1st quarter. Ikarian Capital LLC now owns 409,355 shares of the company’s stock valued at $618,000 after purchasing an additional 9,355 shares during the period. Acadian Asset Management LLC bought a new stake in shares of Karyopharm Therapeutics in the second quarter valued at approximately $167,000. Point72 DIFC Ltd bought a new stake in shares of Karyopharm Therapeutics in the second quarter valued at approximately $31,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Karyopharm Therapeutics in the second quarter worth $494,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Karyopharm Therapeutics during the second quarter worth $143,000. 66.44% of the stock is owned by institutional investors and hedge funds.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).
Further Reading
- Five stocks we like better than Karyopharm Therapeutics
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Tesla Investors Continue to Profit From the Trump Trade
- Short Selling: How to Short a Stock
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- How to Invest in Blue Chip Stocks
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.